Biosimilar CT-P13 Demonstrates Equivalent Safety and Efficacy in Treatment of Crohn’s Disease

Choice of Drug Could Be Based on Lower Cost

A study published in the Annals of Internal Medicine found that the infliximab biosimilar CT-P13 (Celltrion Inc.) demonstrated equivalent safety and efficacy to the anti-tumor necrosis factor (TNF) monoclonal antibody for treating Crohn’s disease in infliximab-naïve patients.

TNF inhibitors, including infliximab, have improved the management of inflammatory bowel disease. As CT-P13 demonstrated efficacy and safety for some inflammatory arthritides, it was approved for Crohn’s disease on that basis, without specific studies examining its effects in Crohn’s disease.

Researchers from Caisse Nationale de l’Assurance Maladie in Paris, France, studied a French nationwide database to compare the effectiveness and safety of CT-P13 and the reference product (infliximab). The study included 5,050 infliximab-naïve patients who commenced treatment with infliximab (n = 2,551) or CT-P13 (n = 2,499). Researchers found that CT-P13 demonstrated equivalent efficacy to infliximab and they observed no difference regarding safety outcomes.

Based on the study’s findings, it’s possible that choosing between infliximab and CT-P13 could be based primarily on cost.

Source: MedicalXpress.com, December 11, 2018